[{"notes_id":"1_886","category":"8","subcategory":"0","title":"Allopurinol","body":"Allopurinol is used in the prevention of gout. It works by inhibiting <span class=\"concept\" data-cid=\"908\">xanthine oxidase<\/span>.<br \/><br \/>Initiating allopurinol prophylaxis<br \/><ul><li>it has traditionally been taught that urate-lowering therapy (ULT) should not be started until 2 weeks after an acute attack, as starting too early may precipitate a further attack. The evidence base to support this however looks weak<\/li><li>in 2017 the BSR updated their guidelines. They still support a delay in starting urate-lowering therapy because it is better for a patient to make long-term drug decisions whilst not in pain<ul><li>the key passage is: <i>'Commencement of ULT is best delayed <span class=\"concept\" data-cid=\"4354\">until inflammation has settled as ULT is better discussed when the patient is not in pain<\/span>'<\/i><\/li><\/ul><\/li><li>initial dose of 100 mg od, with the dose titrated every few weeks to aim for a serum uric acid of < 300 \u00b5mol\/l. Lower initial doses should be given if the patient has a reduced eGFR<\/li><li>colchicine cover should be considered when starting allopurinol. NSAIDs can be used if colchicine cannot be tolerated. The BSR guidelines suggest this may need to be continued for 6 months<\/li><\/ul><br \/>Indications for allopurinol<br \/><ul><li>the British Society of Rheumatology Guidelines now advocate offering <span class=\"concept\" data-cid=\"5124\">urate-lowering therapy to all patients after their <b>first attack of gout<\/b><\/span><\/li><li>ULT is <i>particularly<\/i> recommended if:<ul><li>>= 2 attacks in 12 months<\/li><li>tophi<\/li><li>renal disease<\/li><li>uric acid renal stones<\/li><li>prophylaxis if on cytotoxics or diuretics<\/li><\/ul><\/li><li>patients with Lesch-Nyhan syndrome often take allopurinol for life<\/li><\/ul><br \/><br \/><h5 class='notes-heading'>Adverse effects<\/h5><br \/>The most significant adverse effects are dermatological and patients should be warned to stop allopurinol immediately if they develop a rash:<br \/><ul><li>severe cutaneous adverse reaction (SCAR)<\/li><li>drug reaction with eosinophilia and systemic symptoms (DRESS)<\/li><li>Stevens-Johnson syndrome<\/li><\/ul><br \/>Certain ethnic groups such as the Chinese, Korean and Thai people seem to be at an increased risk of these dermatological reactions.<br \/><br \/><span class=\"concept\" data-cid=\"9896\">Patients at a high risk of severe cutaneous adverse reaction should be screened for the HLA-B *5801 allele<\/span>.<br \/><br \/><br \/><h5 class='notes-heading'>Interactions<\/h5><br \/><span class=\"concept\" data-cid=\"5722\">Azathioprine<\/span><br \/><ul><li>metabolised to active compound 6-mercaptopurine<\/li><li>xanthine oxidase is responsible for the oxidation of 6-mercaptopurine to 6-thiouric acid<\/li><li>allopurinol can therefore lead to high levels of 6-mercaptopurine<\/li><li>a much reduced dose (e.g. 25%) must therefore be used if the combination cannot be avoided<\/li><\/ul><br \/>Cyclophosphamide<br \/><ul><li>allopurinol reduces renal clearance, therefore may cause marrow toxicity<\/li><\/ul><br \/>Theophylline<br \/><ul><li><span class=\"concept\" data-cid=\"5723\">allopurinol causes an increase in plasma concentration of theophylline by inhibiting its breakdown<\/span><\/li><\/ul>","notes_hash":"bdcc94bd13c514600b92bf0b6ff23d59","knowledge_graph_node_id_link":10890,"links":"<table style='width:100%'><tr><td>BNF<\/td><td style = \"float: right;width:115px;\"><button type=\"button\" style=\"\" id=\"link_like_1969\" data-linkid=\"1969\" data-rating=\"1\" class=\"rate-link btn btn-link\"><svg class=\"bi bi-hand-thumbs-up\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-up\"\/><\/svg><\/button><span id=\"link_good_count_1969\" class = \"link_good_count\" style=\"color:green; font-size:85%;\">1<\/span><button type=\"button\" style=\"\" id=\"link_dislike_1969\" data-linkid=\"1969\" data-rating=\"0\" class=\"rate-link btn btn-link\"><svg class=\"bi bi-hand-thumbs-down\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-down\"\/><\/svg><\/button><span id=\"link_bad_count_1969\" class = \"link_bad_count\" style=\"color:red; font-size:85%;\">1<\/span><\/td><\/tr><tr><td colspan=\"2\"><a target=\"_blank\" href=\"https:\/\/bnf.nice.org.uk\/drug\/allopurinol.html\">Allopurinol<\/a><\/td><\/tr><\/table><br><br><table style='width:100%'><tr><td>British Society of Rheumatology<\/td><td style = \"float: right;width:115px;\"><button type=\"button\" style=\"\" id=\"link_like_1966\" data-linkid=\"1966\" data-rating=\"1\" class=\"rate-link btn btn-link\"><svg class=\"bi bi-hand-thumbs-up\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-up\"\/><\/svg><\/button><span id=\"link_good_count_1966\" class = \"link_good_count\" style=\"color:green; font-size:85%;\">2<\/span><button type=\"button\" style=\"\" id=\"link_dislike_1966\" data-linkid=\"1966\" data-rating=\"0\" class=\"rate-link btn btn-link\"><svg class=\"bi bi-hand-thumbs-down\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-down\"\/><\/svg><\/button><span id=\"link_bad_count_1966\" class = \"link_bad_count\" style=\"color:red; font-size:85%;\">1<\/span><\/td><\/tr><tr><td colspan=\"2\"><a target=\"_blank\" href=\"https:\/\/academic.oup.com\/rheumatology\/article\/56\/7\/1056\/3855178\">2017 Gout guidelines<\/a><\/td><\/tr><\/table>","media":"","concepts_for_notes":{"908":{"concept_text":"Allopurinol inhibits xanthine oxidase","concept_percentile":"9"},"5124":{"concept_text":"Offer allopurinol to all patients after their first attack of gout ","concept_percentile":"86"},"5722":{"concept_text":"Allopurinol increases risk of azathioprine toxicity","concept_percentile":"74"}},"category_name":"Pharmacology and therapeutics","subcategory_name":"","comment_count":5},"",[]]